文献速递慢性肾脏病

DNA甲基化谱识别糖尿病慢性肾脏病早期与晚期的表观遗传差异

DNA methylation profiling identifies epigenetic differences between early versus late stages of diabetic chronic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

该横断面表观基因组关联研究纳入119名成人,比较早期与晚期糖尿病相关CKD患者的DNA甲基化差异。研究发现239个CpG位点可将两组 largely 区分,并识别出CRISP2和PIWIL1两个差异甲基化区域;8个CpG位点组合预测两组的AUC达0.976。

要点

  • 早期与晚期糖尿病CKD患者存在 distinct DNA甲基化模式。
  • CRISP2和PIWIL1基因可能作为阶段特异性标志物。
  • 8个CpG位点组合对两组预测的AUC为0.976。

核心结论

  • 早期与晚期糖尿病CKD患者存在 distinct DNA甲基化模式,并发现特定CpG位点可能随CKD分期进展而改变。

研究设计与样本

  • 横断面表观基因组关联研究,招募119名成人,从血液提取DNA,使用Illumina Infinium MethylationEPIC BeadChips(HM850K)进行全基因组甲基化分析。

主要发现

  • 对239个CpG位点(未校正P值<0.01且甲基化绝对变化5%)进行层次聚类, largely 区分早期与晚期组。
  • 热图显示239个CpG位点在早期与晚期组间呈现 distinct 甲基化模式,部分位点显示渐进性变化证据。
  • 差异甲基化区域分析突出CRISP2和PIWIL1两个基因。
  • 仅使用8个CpG位点组合预测两组的受试者工作特征曲线下面积(AUC)为0.976。

临床怎么用

  • 检测特定CpG位点甲基化水平可能有助于区分糖尿病CKD早期与晚期。
  • CRISP2和PIWIL1基因有望作为阶段特异性糖尿病相关CKD标志物。

局限性

  • 横断面设计无法确定甲基化变化与CKD进展的因果关系。
  • 样本量有限(119名成人),需更大队列验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We investigated a cross-sectional epigenome-wide association study of patients with early and late diabetes-associated chronic kidney disease (CKD) to identify possible epigenetic differences between the two groups as well as changes in methylation across all stages of diabetic CKD. We also evaluated the potential of using a panel of identified 5'-C-phosphate-G-3' (CpG) sites from this cohort to predict the progression of diabetic CKD. METHODS: This cross-sectional study recruited 119 adults. DNA was extracted from blood using the Qiagen QIAampDNA Mini Spin Kit. Genome-wide methylation analysis was performed using Illumina Infinium MethylationEPIC BeadChips (HM850K). Intensity data files were processed and analysed using the minfi and MissMethyl packages for R. We examined the degree of methylation of CpG sites in early versus late diabetic CKD patients for CpG sites with an unadjusted P-value <0.01 and an absolute change in methylation of 5% (n = 239 CpG sites). RESULTS: Hierarchical clustering of the 239 CpG sites largely separated the two groups. A heat map for all 239 CpG sites demonstrated distinct methylation patterns in the early versus late groups, with CpG sites showing evidence of progressive change. Based on our differentially methylated region (DMR) analysis of the 239 CpG sites, we highlighted two DMRs, namely the cysteine-rich secretory protein 2 (CRISP2) and piwi-like RNA-mediated gene silencing 1 (PIWIL1) genes. The best predictability for the two groups involved a receiver operating characteristics curve of eight CpG sites alone and achieved an area under the curve of 0.976. CONCLUSIONS: We have identified distinct DNA methylation patterns between early and late diabetic CKD patients as well as demonstrated novel findings of potential progressive methylation changes across all stages (1-5) of diabetic CKD at specific CpG sites. We have also identified associated genes CRISP2 and PIWIL1, which may have the potential to act as stage-specific diabetes-associated CKD markers, and showed that the use of a panel of eight identified CpG sites alone helps to increase the predictability for the two groups.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Lecamwasam A, Novakovic B, Meyer B, et al. DNA methylation profiling identifies epigenetic differences between early versus late stages of diabetic chronic kidney disease. Nephrol Dial Transplant. 2021. PMID: 33146725. doi:10.1093/ndt/gfaa226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。